German mRNA specialist moves into Animal Health in collaboration with Bayer

11/05/2016 - 2 minutes

BioNTech is joining its mRNA technology with Bayer’s expertise in veterinary applications in a new collaboration – to develop first-in-class vaccines for animals.

bayer_biontech_mrna_therapy_animalsBased in Mainz (Germany), BioNTech is the largest private Biotech in Europe.

Along with its CAR-T and TCR programmes, BioNTech is developing mRNA therapies – a promising field in medicine. These include immunotherapies for cancer, vaccines against infectious diseases and protein replacement for rare genetic diseases.

The mRNA expertise of BioNTech has not only yielded several candidates for its pipeline, but also a €1.37Bn deal with Sanofi.

Now, it’s Bayer’s turn. The German company, active in both healthcare and agriculture, is securing exclusive rights to use BioNTech’s proprietary mRNA technology in Animal Health applications.

The objective is to develop mRNA vaccines for different species of pets and farm animals. Bayer is bringing its own expertise in the veterinary area – the company developed and commercialises several veterinary medicines.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member